Similar articles

• Support for the RV144 HIV vaccine trial.

  Belshe R, Franchini G, Girard MP, Gotch F, Kaleebu P, Marthas ML, McChesney MB, McCullough R, Mhalu F, Salmon-Ceron D, Sekaly RP, van Rompay K, Verrier B, Wahren B, Weissenbacher M. Belshe R, et al. Science. 2004 Jul 9;305(5681):177-80; author reply 177-80. doi: 10.1126/science.305.5681.177b. Science. 2004. PMID: 15247455 No abstract available.
• Public health. A sound rationale needed for phase III HIV-1 vaccine trials.

  Burton DR, Desrosiers RC, Doms RW, Feinberg MB, Gallo RC, Hahn B, Hoxie JA, Hunter E, Korber B, Landay A, Lederman MM, Lieberman J, McCune JM, Moore JP, Nathanson N, Picker L, Richman D, Rinaldo C, Stevenson M, Watkins DI, Wolinsky SM, Zack JA. Burton DR, et al. Science. 2004 Jan 16;303(5656):316. doi: 10.1126/science.1094620. Science. 2004. PMID: 14726576 No abstract available.
• Outstanding questions on HIV vaccine trial.

  Jefferys R, Harrington M. Jefferys R, et al. Science. 2004 Jul 9;305(5681):180; author reply 180. doi: 10.1126/science.305.5681.180a. Science. 2004. PMID: 15247456 No abstract available.
• Therapeutic vaccine trails in Thailand.

  Churdboonchart V. Churdboonchart V. J HIV Ther. 2004 Sep;9(3):57-9. J HIV Ther. 2004. PMID: 15534562 Review.
• HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand.

  Rerks-Ngarm S, Brown AE, Khamboonruang C, Thongcharoen P, Kunasol P. Rerks-Ngarm S, et al. AIDS. 2006 Jul 13;20(11):1471-9. doi: 10.1097/01.aids.0000237362.26370.f8. AIDS. 2006. PMID: 16847401 Review. No abstract available.